In the NAFLD‐cohort 2, we found statistically significant increases in the levels of PIGR by 157%, galectin‐3 binding protein (LGALS3BP) by 102%, and AFM by 58% (Fig 3C and D). The gene discussed is LGALS3BP; the disease is metabolic dysfunction-associated steatotic liver disease.